Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of AVP-786 for agitation in Alzheimer's disease dementia
NL-OMON52046Phase 3Not yet recruiting
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jul 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing AVP-786 with Placebo (2 arms). Primary endpoint: Cohen-Mansfield Agitation Inventory total score. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
deudextromethorphan
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON52046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52046.